Protest of Application No. 10/550,382 (U.S. National Stage of International Application No. PCT/EP2004/003590)

Exhibit D

Compounds

1) Figure 1 --10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide ("OXC")

<u>2) Figure 2--10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide</u> ("MHD")

R₁ (in formula I of the '590 application) is hydrogen

Also known as:

- 10,11-dihydro-10-hydroxycarbamazepine
- Monohydroxy derivative (MHD)
- BIA 2-005

The S(+) enantiomer is known as:

- S-(+)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
- S-MHD
- Eslicarbazepine

The R(-) enantiomer is also known as:

- R-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
- R-MHD

Licarbazepine

3) Figure 3--10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

R₁ (in formula I of the '590 application) is C₁ alkyl carbonyl (acetyl)

The S(-) enantiomer is known as:

- S-(-)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
- Eslicarbazepine acetate
- BIA 2-093

4) Figure 4--10-propionyloxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

R₁ (in formula I of the '590 application) is C₂ alkyl carbonyl

5) Figure 5--10-butyryloxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

R_1 (in formula I of the '590 application) is C_3 alkyl carbonyl

$$\bigcap_{\mathsf{H}_2\mathsf{N}} \bigcap_{\mathsf{O}} \bigcap_{\mathsf{H}_2\mathsf{N}} \bigcap_{\mathsf{O}} \bigcap_{\mathsf{H}_2\mathsf{N}} \bigcap_{\mathsf{O}} \bigcap_{\mathsf{H}_2\mathsf{N}} \bigcap_{\mathsf{O}} \bigcap_{\mathsf{O}} \bigcap_{\mathsf{C}} \bigcap_{\mathsf$$